Abstract:Introduction: Colorectal cancer (CRC) remains a significant cause of cancer related mortality. Fat mass and obesity-associated protein (FTO) is a m6A mRNA demethylase that plays an oncogenic role in various malignancies. In this study we evaluated the role of FTO in CRC tumorigenesis. Methods: Cell proliferation assays were conducted in 6 CRC cell lines with the FTO inhibitor CS1 (50-3200 nM) (± 5-FU 5-80 mM) and after lentivirus mediated FTO knockdown. Cell cycle and apoptosis assays were conducted in HCT116 cells (24 h and 48 h, 290 nM CS1). Western blot and m6A dot plot assays were performed to assess CS1 inhibition of cell cycle proteins and FTO demethylase activity. Migration and invasion assays of shFTO cells and CS1 treated cells were performed. An in vivo heterotopic model of HCT116 cells treated with CS1 or with FTO knockdown cells was performed. RNA-seq was performed on shFTO cells to assess which molecular and metabolic pathways were impacted. RT-PCR was conducted on select genes down-regulated by FTO knockdown. Results: We found that the FTO inhibitor, CS1 suppressed CRC cell proliferation in 6 colorectal cancer cell lines and in the 5-Fluorouracil resistant cell line (HCT116-5FUR). CS1 induced cell cycle arrest in the G2/M phase by down regulation of CDC25C and promoted apoptosis of HCT116 cells. CS1 suppressed in vivo tumor growth in the HCT116 heterotopic model (p< 0.05). Lentivirus knockdown of FTO in HCT116 cells (shFTO) mitigated in vivo tumor proliferation and in vitro demethylase activity, cell growth, migration and invasion compared to shScr controls (p< 0.01). RNA-seq of shFTO cells compared to shScr demonstrated down-regulation of pathways related to oxidative phosphorylation, MYC and Akt/ mTOR signaling pathways. Discussion: Further work exploring the targeted pathways will elucidate precise downstream mechanisms that can potentially translate these findings to clinical trials.

A Novel Inhibitor of the Obesity-Related Protein FTO.

Identification of A Novel Small-Molecule Binding Site of the Fat Mass and Obesity Associated Protein (FTO)

Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors

Crystal Structure of the FTO Protein Reveals Basis for Its Substrate Specificity

A novel inhibitor of N6-methyladenosine demethylase FTO induces mRNA methylation and shows anti-cancer activities

Studies on the fat mass and obesity-associated (FTO) gene and its impact on obesity-associated diseases

Identification of Natural Compound Radicicol As a Potent FTO Inhibitor.

Fluorescein Derivatives As Bifunctional Molecules for the Simultaneous Inhibiting and Labeling of Fto Protein

Structure‐Activity Relationships of 2‐(Arylthio)benzoic Acid FTO Inhibitors

FTO regulates adipogenesis by controlling cell cycle progression via mA-YTHDF2 dependent mechanism.

FTO gene polymorphisms and obesity risk in Chinese population: a meta-analysis

Identification of Specific N 6 -Methyladenosine RNA Demethylase FTO Inhibitors by Single-Quantum-Dot-Based FRET Nanosensors

Lose weight with traditional chinese medicine? Potential suppression of fat mass and obesity-associated protein.

FTO is a Transcriptional Repressor to Auto-Regulate Its Own Gene and Potentially Associated with Homeostasis of Body Weight.

Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5

Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1

Development of cell-active N6-methyladenosine RNA demethylase FTO inhibitor.

Discovery of Core-Structurally Novel PTP1B Inhibitors with Specific Selectivity Containing Oxindole-Fused Spirotetrahydrofurochroman by One-Pot Reaction.

Targeting fat mass and obesity-associated protein mitigates human colorectal cancer growth in vitro and in a murine model

Trna-Derived Small Non-Coding RNAs As Novel Epigenetic Molecules Regulating Adipogenesis

Aberrant elevation of FTO levels promotes liver steatosis by decreasing the m<SUP>6</SUP>A methylation and increasing the stability of SREBF1 and ChREBP mRNAs